Compare Coinbase Global, Inc. (COIN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coinbase Global, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Coinbase Global, Inc. trades at $179.39 (market cap $45.38B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Coinbase Global, Inc. is far larger — about 4.5× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Coinbase Global, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Coinbase Global, Inc. for 78 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| COIN | XBI | |
|---|---|---|
Market Cap | $45.38B | $10.11B |
Volume | 11,013,940 | 12,903,266 |
Sector | Financials | Broad Market / Factor |
52-Week High | $387.00 | $169.55 |
52-Week Low | $141.09 | $104.99 |
Typical Hold Time | 78 Days | 38 Days |
Enterprise Value | $43.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coinbase Global (COIN) trades at $172.00, down 3.61% on the day, with a mixed technical picture showing bullish oscillators but bearish moving averages. The company reported strong revenue growth to $7.18 billion in 2025 but missed Q2 2026 EPS expectations. Recent developments include CFTC approval for derivatives clearing and expanded partnerships with Citigroup for stablecoin payments, positioning the company for future growth in digital financial services.
The stock presents a compelling risk-reward profile with analyst consensus pointing to 23% upside to the $211.91 price target. However, investors face significant execution risks amid volatile earnings performance and regulatory uncertainty in the financial technology sector. The company's transition toward diversified revenue streams beyond Bitcoin trading remains a key catalyst for long-term value creation.
XBI trades at $153.75, up 2.34% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts like the Merck-Moderna cancer vaccine breakthrough.
Outlook remains mixed with 100% analyst hold rating contrasting with bullish news catalysts. Key risks include high volatility, sector-specific regulatory pressures, and expense ratios higher than broader healthcare ETFs. The current technical setup near resistance requires monitoring for breakout confirmation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
